Report of adverse events of special interest (AESIs) for sintilimab plus a bevacizumab biosimilar (IBI305) in unresectable hepatocellular carcinoma. A multicenter study to investigate the role of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results